



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

SEP 25 2000

Robert J. Baran  
Allergan, Inc.  
2525 Dupont Drive  
Irvine CA 92612

Re: Patent Term Extension  
Application for  
U.S. Patent No. 5,089,509


Dear Mr. Baran:

A certificate under 35 U.S.C. § 156 is enclosed extending the term of U.S. Patent No. 5,089,509 for a period of 845 days.

While a courtesy copy of this letter is being forwarded to the Food and Drug Administration (FDA), you should directly correspond with the FDA regarding any required changes to the patent expiration dates set forth in the Patent and Exclusivity Data Appendix of the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) or in the Patent Information set forth in the Green Book (FDA Approved Animal Drug Products). The communication to FDA should include sending a copy of the certificate of extension to New Drug Application and another copy of the certificate of extension to Mary Ann Holovac, who will update the Orange Book. Mary Ann's address is

CDER OIT DDMS  
NLRC 235 (HFD-090)  
5516 Nicholson Lane  
Kensington, MD 20895

Telephone inquiries regarding this communication should be directed to the undersigned at (703)306-3159.

  
Karin Tyson  
Senior Legal Advisor  
Office of Patent Legal Administration  
Office of the Deputy Commissioner  
for Patent Examination Policy

cc: David T. Read  
Acting Director Regulatory Policy Staff, CDER  
Food and Drug Administration  
1451 Rockville Pike, HFD-7  
Rockville, MD 20852

Re: TAZORAC® (tazarotene)  
FDA Docket No. 98E-0474

# UNITED STATES PATENT AND TRADEMARK OFFICE

## CERTIFICATE EXTENDING PATENT TERM UNDER 35 U.S.C. § 156

PATENT NO. : 5,089,509  
ISSUED : February 18, 1992  
INVENTOR : Roshantha A. S. Chandraratna  
PATENT OWNER : Allergan, Inc.  
PRODUCT : TAZORAC® (tazarotene)

This is to certify that an application under 35 U.S.C. § 156 has been filed in the U.S. Patent and Trademark Office, requesting extension of the term of U.S. Patent No. 5,089,509 based upon the regulatory review of the product TAZORAC® (tazarotene) by the Food and Drug Administration. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

845 days

from February 18, 2009, the original expiration date of the patent, subject to the provisions of 35 U.S.C. § 41(b), with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).



I have caused the seal of the U.S. Patent and Trademark Office to be affixed this 12th day of September 2000.

A handwritten signature in black ink, appearing to read "Q. Todd Dickinson", is written over the text.

Q. Todd Dickinson  
Under Secretary of Commerce for Intellectual Property  
and Director of the United States Patent and  
Trademark Office